Brookline Capital Management initiated coverage on shares of Vaxart (NASDAQ:VXRT) in a research report report published on Thursday morning, The Fly reports. The brokerage issued a buy rating and a $6.00 price objective on the biotechnology company’s stock.
A number of other analysts have also recently commented on the stock. ValuEngine raised shares of Vaxart from a hold rating to a buy rating in a research note on Thursday, August 1st. HC Wainwright initiated coverage on shares of Vaxart in a research note on Thursday, June 27th. They set a buy rating and a $2.00 target price for the company.
VXRT stock opened at $0.64 on Thursday. The stock has a market capitalization of $10.22 million, a P/E ratio of -0.24 and a beta of 0.50. The firm has a 50-day simple moving average of $0.69 and a 200-day simple moving average of $1.12. The company has a quick ratio of 1.78, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. Vaxart has a 52 week low of $0.55 and a 52 week high of $7.60.
Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.